Related Experiment Video
Updated: Jul 6, 2026
05:57
The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
Published on: May 17, 2024
Management of hyperhomocysteinemia
1Section of Endocrinology, Department of Medicine, Tulane University Medical School, New Orleans, Louisiana.
Metabolic Syndrome and Related Disorders
|March 29, 2008
Summary
High homocysteine levels are linked to cardiovascular disease. While supplements like B vitamins and betaine show promise, more clinical trials are needed to confirm their benefits for heart health.
Area of Science:
- Cardiovascular Medicine
- Nutritional Science
- Metabolic Disorders
Background:
- Hyperhomocysteinemia is a known risk factor for cardiovascular disease (CVD).
- Modifying traditional CVD risk factors improves outcomes, prompting investigation into hyperhomocysteinemia treatment.
- Vitamins B6, B12, folate, and betaine are involved in homocysteine metabolism.
Purpose of the Study:
- To explore the potential benefits of treating hyperhomocysteinemia for cardiovascular outcomes.
- To review current treatment strategies and identify knowledge gaps regarding supplement efficacy and dosage.
- To determine if lowering homocysteine levels translates to improved clinical endpoints.
Main Methods:
- Review of existing literature on hyperhomocysteinemia treatment using B vitamins and betaine.
- Analysis of studies examining various supplement doses, combinations, and treatment durations.
- Evaluation of evidence linking homocysteine reduction to cardiovascular outcomes.
Main Results:
- Supplements like B vitamins and betaine are used in various regimens for hyperhomocysteinemia with reported favorable outcomes.
- Consensus on optimal treatment (e.g., folic acid alone vs. combination therapy) is lacking.
- Optimal dosage for normalizing homocysteine, especially in specific patient groups (e.g., renal disease), requires further determination.
- Observed benefits are primarily in surrogate cardiovascular outcomes, not definitive clinical endpoints.
Conclusions:
- The clinical benefit of treating hyperhomocysteinemia requires confirmation through trials demonstrating improved clinical endpoints.
- In patients with CVD and few traditional risk factors, investigating and treating hyperhomocysteinemia is warranted.
- Further research is needed to establish definitive treatment guidelines and clinical efficacy.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:23Hypertension V: Nursing Management
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...